Literature DB >> 24462038

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Prashant R Tembhare1, Constance M Yuan1, David Venzon2, Raul Braylan3, Neha Korde4, Elisabet Manasanch4, Diamond Zuchlinsky5, Katherine Calvo3, Roger Kurlander3, Manisha Bhutani5, Nishant Tageja5, Irina Maric3, Marcia Mulquin5, Mark Roschewski5, Mary Kwok4, David Liewehr2, Ola Landgren5, Maryalice Stetler-Stevenson6.   

Abstract

Flow cytometric (FC) enumeration of abnormal plasma cells (APCs) for diagnosis and prognostication of plasma cell dyscrasias (PCD) is challenging. We studied antigen expression in normal plasma cells (NPC) (N = 34) and APC in a series of unselected PCD (N = 59). NPC subpopulations often demonstrated CD19(-), CD20(+), CD45(-) or dim and CD56(+), an immunophenotype observed in PCD. However abnormal CD81 was only observed in APCs (APC detection sensitivity 95%; specificity 100%). We evaluated differences in antigen expression patterns among MGUS (N = 14), SMM (N = 35) and MM (N = 10), finding the combination of CD45 and CD56 helpful in differentiating MGUS from SMM and MM (p = 0.0002). Published by Elsevier Ltd.

Entities:  

Keywords:  CD81; Monoclonal gammopathy of uncertain significance; Multiple myeloma; Normal plasma cell immunophenotype; Smoldering multiple myeloma

Mesh:

Substances:

Year:  2013        PMID: 24462038      PMCID: PMC3947595          DOI: 10.1016/j.leukres.2013.12.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  28 in total

1.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

Authors:  Grzegorz S Nowakowski; Thomas E Witzig; David Dingli; Michal J Tracz; Morie A Gertz; Martha Q Lacy; John A Lust; Angela Dispenzieri; Philip R Greipp; Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

2.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

Authors:  A C Rawstron; R G Owen; F E Davies; R J Johnson; R A Jones; S J Richards; P A Evans; J A Child; G M Smith; A S Jack; G J Morgan
Journal:  Br J Haematol       Date:  1997-04       Impact factor: 6.998

3.  Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Authors:  Sergej Konoplev; L Jeffrey Medeiros; Carlos E Bueso-Ramos; Jeffrey L Jorgensen; Pei Lin
Journal:  Am J Clin Pathol       Date:  2005-09       Impact factor: 2.493

4.  Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Authors:  B Paiva; N-C Gutiérrez; X Chen; M-B Vídriales; M-Á Montalbán; L Rosiñol; A Oriol; J Martínez-López; M-V Mateos; L López-Corral; E Díaz-Rodríguez; J-J Pérez; E Fernández-Redondo; F de Arriba; L Palomera; E Bengoechea; M-J Terol; R de Paz; A Martin; J Hernández; A Orfao; J-J Lahuerta; J Bladé; A Pandiella; J-F San Miguel
Journal:  Leukemia       Date:  2012-02-15       Impact factor: 11.528

5.  High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.

Authors:  J Almeida; A Orfao; M Ocqueteau; G Mateo; M Corral; M D Caballero; J Blade; M J Moro; J Hernandez; J F San Miguel
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

6.  Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.

Authors:  T E Witzig; T Kimlinger; M Stenson; T Therneau
Journal:  Leuk Lymphoma       Date:  1998-09

7.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Authors:  Pei Lin; Rebecca Owens; Guido Tricot; Carla S Wilson
Journal:  Am J Clin Pathol       Date:  2004-04       Impact factor: 2.493

8.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors:  M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

10.  Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.

Authors:  G S Jensen; M J Mant; A J Belch; J R Berenson; B A Ruether; L M Pilarski
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

View more
  28 in total

1.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

2.  Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Authors:  Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson
Journal:  Leuk Lymphoma       Date:  2014-10-30

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

4.  Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.

Authors:  Dominik F Draxler; Lisa M Wutzlhofer; Georg Slavka; Wolfgang Hübl; Heinz Ludwig; Martin Schreder; John Reynolds; Martin Willheim
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-07       Impact factor: 0.900

5.  Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

Authors:  Alfred L Garfall; Marcela V Maus; Wei-Ting Hwang; Simon F Lacey; Yolanda D Mahnke; J Joseph Melenhorst; Zhaohui Zheng; Dan T Vogl; Adam D Cohen; Brendan M Weiss; Karen Dengel; Naseem D S Kerr; Adam Bagg; Bruce L Levine; Carl H June; Edward A Stadtmauer
Journal:  N Engl J Med       Date:  2015-09-10       Impact factor: 91.245

Review 6.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.

Authors:  Dalia A Salem; Irina Maric; Constance M Yuan; David J Liewehr; David J Venzon; James Kochenderfer; Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2018-07-18       Impact factor: 3.156

8.  Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Authors:  Alfred L Garfall; Edward A Stadtmauer; Wei-Ting Hwang; Simon F Lacey; Jan Joseph Melenhorst; Maria Krevvata; Martin P Carroll; William H Matsui; Qiuju Wang; Madhav V Dhodapkar; Kavita Dhodapkar; Rituparna Das; Dan T Vogl; Brendan M Weiss; Adam D Cohen; Patricia A Mangan; Emily C Ayers; Selene Nunez-Cruz; Irina Kulikovskaya; Megan M Davis; Anne Lamontagne; Karen Dengel; Naseem Ds Kerr; Regina M Young; Donald L Siegel; Bruce L Levine; Michael C Milone; Marcela V Maus; Carl H June
Journal:  JCI Insight       Date:  2018-04-19

9.  GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Authors:  Karthik A Ganapathi; Danielle M Townsley; Amy P Hsu; Diane C Arthur; Christa S Zerbe; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Sergio D Rosenzweig; Raul C Braylan; Neal S Young; Steven M Holland; Katherine R Calvo
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

10.  Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Authors:  Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.